Ofatumumab

Evidence Level: L2

Predicted Indications: 10

Ofatumumab
Ofatumumab: From Chronic Lymphocytic Leukemia to Follicular Lymphoma

## Pharmacist Assessment Report

Ofatumumab: From Chronic Lymphocytic Leukemia to Follicular Lymphoma

One-Sentence Summary

Ofatumumab is a fully human anti-CD20 monoclonal antibody historically approved (as Arzerra) for chronic lymphocytic leukemia (CLL), though it is currently not marketed in Taiwan (0 licenses) and its Taiwan approved-indication text is not on file. Among 10 TxGNN-predicted indications in this evidence pack, the strongest and most clinically credible new signal is Follicular Lymphoma, supported by 16 clinical trials (including one randomized Phase 2 trial) and 18 publications. Note: several other TxGNN predictions in this pack (ranked #1, #2, #5) are CLL/SLL or its molecular subtypes — these likely overlap with ofatumumab’s known historical indication rather than representing genuinely new repurposing opportunities; this is flagged as a probable data gap in the original_indications field.

Quick Overview

Item	Content
Original Indication	Not available from Taiwan regulatory data (0 licenses on file). Evidence within this pack indicates ofatumumab was historically approved internationally as Arzerra for CLL, withdrawn from market in 2019 — this is contextual information, not TFDA-sourced
Predicted New Indication	Follicular Lymphoma
TxGNN Prediction Score	99.70% (score 0.99701, rank 3785)
Evidence Level	L2
Market Status (Taiwan)	✗ Not marketed (Not Marketed)
Number of Authorizations	0
Recommended Decision	Proceed with Guardrails

Why is This Prediction Reasonable?

The structured original_moa field is a flagged data gap (DG002), but the mechanism can be reconstructed from the evidence pack’s own trial and literature records: ofatumumab is a fully human IgG1κ monoclonal antibody that binds a distinct small-loop epitope on CD20, depleting CD20-positive B cells via complement-dependent cytotoxicity (CDC) and antibody-dependent cell-mediated cytotoxicity (ADCC) (PMID 18535937, 22830942, NCT01077622).

Follicular lymphoma (FL) and CLL are both CD20-positive, B-cell-lineage lymphoproliferative malignancies. Ofatumumab’s efficacy was originally established in CLL (accelerated FDA approval 2009, EMA conditional approval 2010), and the same CD20-targeting mechanism is directly applicable to FL, which is also a CD20+ mature B-cell neoplasm.

The class analogy is strong: rituximab, the prototypical anti-CD20 antibody, is already standard of care in FL. Multiple prospective trials in this pack (front-line monotherapy, chemoimmunotherapy combinations, and a randomized Phase 2 comparison) directly test ofatumumab in FL populations, moving this beyond a purely mechanistic extrapolation into an indication with dedicated, disease-specific clinical evidence — unlike several other predictions in this pack (e.g., malignant spiradenoma, Langerhans cell histiocytosis) which lack any biological rationale for CD20 involvement.

Clinical Trial Evidence

Trial Number	Phase	Status	Enrollment	Key Findings
NCT01286272	Phase 2 (Randomized)	Completed	135	CALGB 50904: ofatumumab+bendamustine vs. ofatumumab+bendamustine+bortezomib in untreated high-risk FL — highest-grade direct RCT evidence
NCT00394836	Phase 2	Completed	116	Single-arm international multicenter trial of ofatumumab monotherapy in rituximab-refractory FL
NCT01190449	Phase 2	Completed	51	CALGB trial of single-agent ofatumumab in previously untreated stage II–IV FL
NCT01239394	Phase 2	Completed	43	Ofatumumab as initial systemic treatment for indolent B-cell lymphoma, including FL
NCT01077518	Phase 3	Terminated	346	Randomized ofatumumab+bendamustine vs. bendamustine monotherapy in rituximab-unresponsive indolent B-NHL
NCT01294579	Phase 2	Completed	49	Ofatumumab+bendamustine followed by ofatumumab maintenance in relapsed indolent B-NHL (incl. FL)
NCT00494780	Phase 2	Completed	59	Two-dose ofatumumab combined with CHOP in previously untreated FL
NCT02710643	Phase 2	Completed	110	MIRO trial: radiotherapy ± ofatumumab in stage I/II FL, MRD-driven approach
NCT00742144	Phase 1	Completed	6	Japanese safety/tolerability/PK study of ofatumumab in FL and CLL
NCT01397591	Phase 2	Terminated	3	Ofatumumab+bortezomib in relapsed CD20+ DLBCL, FL, or MCL

Literature Evidence

PMID	Year	Type	Journal	Key Findings
31174236	2019	RCT	Cancer	CALGB 50904: ofatumumab+bendamustine ± bortezomib in previously untreated high-risk FL
30723894	2019	Phase 2 Cohort	Br J Haematol	CALGB 50901: single-agent ofatumumab in untreated low/intermediate-risk FL
22389254	2012	Multicenter Cohort	Blood	Ofatumumab monotherapy in rituximab-refractory FL (n=116); ORR 13%
38937025	2024	Cohort	Lancet Haematology	FIL MIRO: local radiotherapy + MRD-driven ofatumumab in early-stage FL, final results
22409295	2012	Phase 2 Cohort	Br J Haematol	Ofatumumab + CHOP (O-CHOP) as frontline chemoimmunotherapy for FL
24443277	2014	PK Study	J Clin Pharmacol	Population pharmacokinetics of ofatumumab across CLL, FL, and RA populations
18390837	2008	Phase 1/2 Trial	Blood	First clinical use of ofatumumab in relapsed/refractory FL
29934061	2018	Evidence Review	Clin Lymphoma Myeloma Leuk	Evidence-based review of anti-CD20 regimens in relapsed/refractory CLL, DLBCL, FL
28983798	2017	Review	Advances in Therapy	20-year review of rituximab (anti-CD20 class) in B-cell hematologic malignancies
21083037	2010	Review	Expert Rev Hematol	Emerging therapeutic strategies in follicular lymphoma

Market Authorization Information (Taiwan)

Currently no marketing authorization records are on file for ofatumumab in Taiwan (taiwan_regulatory.total_licenses = 0, market_status = Not marketed). No approved-indication text is available for extraction.

Cytotoxicity

Ofatumumab is an antineoplastic biologic (anti-CD20 monoclonal antibody used for CD20+ B-cell malignancies), so this section applies.

Item	Content
Cytotoxicity Classification	Immunotherapy — targeted anti-CD20 monoclonal antibody (CDC/ADCC-mediated B-cell depletion, not a conventional cytotoxic agent)
Myelosuppression Risk	Low as monotherapy; Medium when combined with chemotherapy backbones such as bendamustine, CHOP, or fludarabine-cyclophosphamide (as used in most trials above)
Emetogenicity Classification	Low (monoclonal antibody class; infusion-related reactions are the more relevant acute toxicity than emesis)
Monitoring Items	CBC with differential, infusion-reaction monitoring, hepatitis B reactivation screening (standard precaution for anti-CD20 agents), immunoglobulin levels
Handling Protection	Standard biologic infusion precautions; not classified under cytotoxic hazardous-drug handling regulations. Please refer to the SmPC for institution-specific protocols

Safety Considerations

No structured safety data is available in this evidence pack (key_warnings, contraindications, and ddi are all data gaps or empty).

Please refer to the SmPC for safety information.

Conclusion and Next Steps

Decision: Proceed with Guardrails

Rationale: Ofatumumab’s efficacy in Follicular Lymphoma is supported by an L2 evidence base — one randomized Phase 2 trial and multiple single-arm Phase 1/2 studies with consistent mechanistic rationale (anti-CD20 activity established in CLL and validated by the rituximab class precedent in FL). However, the drug currently has zero marketing authorizations in Taiwan, and two blocking/high-severity data gaps (TFDA label warnings/contraindications, structured MOA) remain unresolved.

To proceed, the following is needed:

TFDA product label (warnings, contraindications) — DG001, Blocking, required before any S1 safety assessment
Structured MOA data from DrugBank — DG002, High priority
Manual review of the original_indications data source: this pack shows an empty field despite trial/literature evidence (e.g., NCT00824265, NCT01313689) indicating a prior CLL indication history — likely a data extraction gap rather than a true absence of prior indication
Regulatory pathway assessment for a currently unmarketed (Not marketed) product in Taiwan
Clarification of whether TxGNN predictions ranked #1, #2, and #5 (CLL/SLL and its IGHV subtypes) represent genuinely new indications or rediscovery of the historical indication, before including them in any repurposing decision
Disclaimer

This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.